SHIELD study fails to protect prospects for GlaxoSmithKline's vercirnon
This article was originally published in Scrip
On 23 August 2013, GlaxoSmithKline announced that its oral Crohn's disease candidate vercirnon had failed to meet its primary endpoint in SHIELD-1, the first of four Phase III studies investigating the small molecule inhibitor of C-C chemokine receptor type-9 (CCR9) as a treatment for adults with moderate to severe Crohn's disease. The Phase III failure follows the publication of less than convincing Phase II/III study data. While the IBD market may not suffer from the likely loss of vercirnon, the absence of a commercial bridgehead leaves GlaxoSmithKline excluded from the inflammatory bowel disease (IBD) area.
You may also be interested in...
FDA's COVID-19 Naughty List Now Includes Marketers Of Copper Germ Stoppers, ‘24-Hour’ Hand Sanitizer
Warning letters issued by the US FDA on 28 May target two companies using COVID-19 and other disease-prevention claims to market purported germ-killing products, including a rub touted as 24-hour protection and a line of copper rollers and other implements to disinfect hands and personal items.
Industry-funded survey by Charles River Associates explores diverse perceptions about pricing for high-cost cell treatments – including curative cell and gene therapy – among various stakeholder groups.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.